Pemetrexed A Review of its Use in the Management of Advanced Non-Squamous Non-Small Cell Lung Cancer

被引:27
作者
Baldwin, Claudine M. [1 ]
Perry, Caroline M. [1 ]
机构
[1] Adis, Wolters Kluwer Business, Auckland 0754, New Zealand
关键词
MULTITARGETED ANTIFOLATE LY231514; PHASE-III TRIAL; FOLATE TRANSPORTER; 2ND-LINE TREATMENT; CLINICAL-TRIALS; CHEMOTHERAPY; CISPLATIN; DISODIUM; THERAPY; CYTOTOXICITY;
D O I
10.2165/11202640-000000000-00000
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pemetrexed (Alimta (R)) is a multi-targeted antifolate cytotoxic agent available for use in the treatment of adults with advanced non-squamous non-small cell lung cancer (NSCLC). It is indicated as initial therapy in combination with cisplatin, as monotherapy after prior chemotherapy, and as maintenance monotherapy in patients with locally advanced or metastatic non-squamous NSCLC. Pemetrexed has demonstrated efficacy and is generally well tolerated as a first-line therapy (in combination with cisplatin) and as second-line or maintenance monotherapy in advanced non-squamous NSCLC. While the survival benefits of comparator chemotherapies are retained with pemetrexed, pemetrexed has tolerability advantages that may also translate to pharmacoeconomic benefits, although this has yet to be shown in robust pharmacoeconomic analyses. Pemetrexed is an important option for the management of NSCLC, in particular as targeted therapy in patients with non-squamous histology.
引用
收藏
页码:2279 / 2302
页数:24
相关论文
共 76 条
[31]  
Hollen, LUNG CANC SYMPTOM SC
[32]   Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients [J].
Latz, JE ;
Chaudhary, A ;
Ghosh, A ;
Johnson, RD .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (04) :401-411
[33]   Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells [J].
Li, Tianhong ;
Ling, Yi-He ;
Goldman, I. David ;
Perez-Soler, Roman .
CLINICAL CANCER RESEARCH, 2007, 13 (11) :3413-3422
[34]   Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, Pemetrexed disodium, ALIMTA™) and cisplatin:: A multicenter phase II trial [J].
Manegold, C ;
Gatzemeier, U ;
von Pawel, J ;
Pirker, R ;
Malayeri, R ;
Blatter, J ;
Krejcy, K .
ANNALS OF ONCOLOGY, 2000, 11 (04) :435-440
[35]  
MONAHAN BP, 2005, CANC CHEMOTHERAPY B, P96
[36]   Review of the pemetrexed and gemcitabine combination in patients with advanced-stage non-small cell lung cancer [J].
Monnerat, C. ;
Le Chevalier, T. .
ANNALS OF ONCOLOGY, 2006, 17 :V86-V90
[37]  
Muehlenbein CE, 2009, J CLIN ONCOL, V27
[38]  
*NAT CANC I, NEW LUNG CANC TREATM
[39]  
*NAT COMP CANC NET, NCCN PRACT GUID ONC
[40]  
*NAT I CLIN EXC, DIAGN TREATM LUNG CA